Table 2. Baseline characteristics, tumour molecular markers and post-operative management of patients undergoing primary glioblastoma (GBM) resection.

Missing data: ^athree patients with missing data, ^bone patient with missing data, ^cone patient with missing data, ^dtwo patients with missing data, and ^etwo patients with missing data. PS: performance status, 5-ALA: 5-aminolevulinic acid, MGMT: O(6)-methylguanine-DNA methyltransferase, IDH: isocitrate dehydrogenase.

Patient characteristics	White light (n = 189)	5-ALA (n = 50)
Age (median)	60	58
Sex	Female: 88 (46.6%)	Female: 17 (34.0%)
	Male: 101 (53.4%)	Male: 33 (66.0%)
Pre-operative PS	PS ≤ 1: 126 (66.7%)a	PS ≤ 1: 42 (84.0%)
	PS ≥ 2: 60 (31.7%)a	PS ≥ 2: 8 (16.0%)
Pre-operative deficit	174 (92.0%)	44 (88.0%)
Tumour molecular markers	White light (n = 189)	5-ALA (n = 50)
MGMT methylated	86 (45.5%)	18 (36.0%)b
IDH 1/2 mutation	17 (9.0%)	2 (4.0%)c
Post-operative treatment	White light (n = 189)	5-ALA (n = 50)
Radiotherapy	139 (73.5%)d	40 (80.0%)
Chemotherapy	134 (70.9%)e	41 (82.0%)